Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas

Cairo University (CU)

Status: Unknown

Conditions: Malignant Neoplasm of Salivary Gland; Benign Neoplasm of Salivary Gland

Treatments: Device: enzyme linked immunosorbent assay (ELISA)

Study type: Observational

Funder types: Other

Identifiers

NCT03687294

yousrarefaey11

Details and patient eligibility

About

in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor

Enrollment: 70 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: .

• Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I
• Benign tumors will be recruited in group II.

Exclusion Criteria:

• Subjects taking any drugs inducing any changes that could affect the salivary glands.
• Pregnant females.
• Subjects having any allergies, infectious or autoimmune diseases.
• Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.

Trial design

70 participants in 2 patient groups

Group I

Description:

patients suffering from malignant salivary gland tumors.

Treatment:

Device: enzyme linked immunosorbent assay (ELISA)

Group II

Description:

patients suffering from benign salivary gland tumors.

Treatment:

Device: enzyme linked immunosorbent assay (ELISA)